Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial
Article in European Journal of Cancer (May 2024)
The most recent citing publications are shown below. View all 23 publications that cite this research output on Dimensions.
Article in European Journal of Cancer (May 2024)
Preprint in bioRxiv (March 2024)
Article in PLOS ONE (March 2024)